Bioinformatics approaches to multi-omics analysis of the potential of CDKN2A as a biomarker and therapeutic target for uterine corpus endometrial carcinoma Nature.com
Ovarian adenomyoma is a rare gynecological tumor with a high misdiagnosis rate, leading many patients to undergo unnecessary surgeries that may affect fertility. Menstrual abdominal pain is the most common …
Endometriosis is a gynecologic condition characterized by the growth of endometrium-like stroma and glandular elements outside of the uterine cavity. The involvement of hormonal dysregulation, specifically estrogen, is well established …
Endometriosis is a complex disease with diverse etiologies, including hormonal, immunological, and environmental factors; however, its exact pathogenesis remains unknown. While surgical approaches are the diagnostic and therapeutic gold standard, …
To highlight the presentation and management of a patient with dysmenorrhea caused by an accessory cavitated uterine malformation (ACUM) while also summarizing the current evidence regarding this pathology.
The association between endometriosis and congenital uterine anomalies (CUAs) has been discussed for decades, but existing evidence about this association is scarce. The aim of our study is to evaluate …
Pregnancy is a special time during which some benign hormonally-responsive lesions could grow and mimic malignancy on clinical evaluation and imaging. Though decidualization of ovarian endometrioma has been reported, little …
Overexpression of the gonadotropin-releasing hormone receptor (GnRH-R) plays a vital role in the advancement of reproductive malignancies such as ovarian, endometrial, and prostate cancer. Peptidomimetic GnRH antagonists are a substantial …
Endometriosis, the growth of endometrial-like tissue outside the uterus, causes chronic pain and infertility in 10 % of reproductive-aged women worldwide. Unfortunately, no permanent cure exists, and current medical and …
PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs; approval of pembrolizumab for locally advanced uterine cervical cancer, and durvalumab and olaparib for advanced …